Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo …

GA Herman, MP O'Brien, E Forleo-Neto… - The Lancet Infectious …, 2022 - thelancet.com
Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …
被引用次数：30 相关文章
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind …

GA Herman, MP O'Brien, E Forleo-Neto… - The Lancet. Infectious …, 2022 - ncbi.nlm.nih.gov
Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo …

GA Herman, MP O'Brien, E Forleo-Neto, N Sarkar, F Isa… - 2022 - cabidigitallibrary.org
Background: There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo …

GA Herman, MP O'Brien, E Forleo-Neto, N Sarkar, F Isa… - 2022 - pubmed.ncbi.nlm.nih.gov
Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo …

GA Herman, MP O'Brien, E Forleo-Neto… - The Lancet Infectious …, 2022 - Elsevier
Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo …

GA Herman, MP O'Brien, E Forleo-Neto… - The Lancet. Infectious …, 2022 - europepmc.org
Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …